Seer Board Defends Strategy Amid Proxy Fight with Radoff-JEC Group
Event summary
- Seer's Board issued a letter to shareholders on July 14, 2026, urging votes for its seven director nominees ahead of the July 28, 2026 Annual Meeting.
- The Board refutes Radoff-JEC Group's claims, arguing the proxy contest is about long-term strategy versus short-term cash extraction.
- Seer highlights a 36% reduction in cash burn since 2022 and disciplined spending to scale its proteomics platform.
- Radoff and Torok have held six meetings with Seer's management and Board since late 2024 but declined customary nominee interviews.
The big picture
Seer's proxy fight reflects broader tensions in life sciences tools between activist investors seeking quick returns and management prioritizing platform-building. The contest underscores the challenge of valuing category-creating technologies that outpace public market recognition. With $150M+ invested since 2022, the outcome will signal investor appetite for long-term bets in proteomics.
What we're watching
- Governance Dynamics
- Whether Seer's Board can maintain control amid activist pressure to pursue short-term liquidity.
- Strategic Execution
- The pace at which Seer scales its proteomics platform while managing cash burn and market perception.
- Investor Sentiment
- How long-term shareholders balance scientific validation against near-term financial performance.
Related topics